1-Bromo-10-fluorodecane | CAS:334-61-2

We serve 1-Bromo-10-fluorodecane CAS:334-61-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-Bromo-10-fluorodecane

Chemical Name:1-Bromo-10-fluorodecane
CAS.NO:334-61-2
Synonyms:1-Bromo-10-fluorodecane
DECANE,1-BROMO-10-FLUORO
10-bromo-1-fluoro-decane
1-Brom-10-fluor-decan
Decane, 1-bromo-10-fluoro-
1-bromo-10-fluoro-decane
Molecular Formula:C10H20BrF
Molecular Weight:239.16800
 
Physical and Chemical Properties:
Density:1.126
Boiling point:264.9ºC
Flash point:117.4ºC
Index of Refraction:1.443
 
Specification:
Appearance:Colorless transparent liquid
Assay:≥99.0%
Moisture:≤0.05%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 1-Bromo-10-fluorodecane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-bromo-10-fluoro-decane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,DECANE,1-BROMO-10-FLUORO Use and application,10-bromo-1-fluoro-decane technical grade,usp/ep/jp grade.


Related News: Any South Korean citizen returning home who has been in Hubei Province within the past two weeks will be subject to 14 days of self-quarantine and monitoring, the government said.11-Bromo-1-Undecene manufacturer Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.Ethyl (E)-hex-2-enoate supplier Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.3-Amino-3-azabicyclo[3.3.0]octane hydrochloride vendor As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.